Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion

• Status: Completed
• Trial end date: 2017-12-23
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Male or female adult patients who suffer from visual impairment due to ME secondary to CRVO

• Anti-VEGF treatment-naive patients who started reimbursed Eylea treatment between the 1st of June 2014 and the 28th of February 2015

Exclusion Criteria:

• Patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.